Phase 2 Parkinson's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 40 to 75 years old (any gender) at the first study visit.
- People who have been diagnosed with idiopathic Parkinson's disease (the most common form, with no known cause) for at least 2 years, based on recognised medical diagnostic guidelines.
- People whose Parkinson's disease is rated at a moderate stage (stage 2 or 3 on a standard scale called the Hoehn and Yahr scale), assessed while not on Parkinson's medication.
- People whose Parkinson's movement symptoms score between 15 and 60 on a standard medical rating scale (MDS-UPDRS Part III), assessed while not on Parkinson's medication.
- People who do not have significant movement complications from their Parkinson's medication (scoring 2 or less on a specific part of the MDS-UPDRS rating scale).
- People who have been on a stable, unchanged Parkinson's medication routine for at least 12 weeks before the first treatment visit, including a daily dose of Parkinson's medications equivalent to at least 300 mg of levodopa — this may include levodopa, certain enzyme inhibitors (COMT or MAO-B inhibitors), or certain dopamine-boosting medications (ergot-derived or non-ergot-derived dopamine agonists), or other recognised Parkinson's medications.
- People whose blood test results at the first visit meet specific health benchmarks, including: a sufficient white blood cell count and platelet count; normal blood-clotting function; liver function within acceptable ranges; and kidney function showing an adequate filtration rate (confirm with trial site for exact values).
- People who are willing and able to attend all required study visits and follow-up appointments.
- People who understand the study procedures and have signed a written consent form (a legal representative may sign on their behalf if needed).
- People who are able to complete all self-reported questionnaires and outcome measures required by the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have been diagnosed with an atypical form of Parkinson's disease or a secondary form of parkinsonism (Parkinson's-like symptoms caused by another condition).
- People who have had brain surgery for Parkinson's disease in the 2 years before the first treatment visit, including deep brain stimulation, pallidotomy, thalamotomy, or any other procedure that may affect movement.
- People who score below 24 on a standard memory and thinking test (the Mini-Mental State Examination) at the first visit.
- People with a significant lifetime history of certain psychiatric conditions — such as alcohol use disorder, drug abuse, or a suicide attempt — that the study doctor believes could interfere with participation.
- People who have had a cancer diagnosis or are currently being treated for cancer within the 2 years before the first treatment visit.
- People with ongoing or recent (within 2 years) serious medical conditions, including: certain heart conditions (such as a heart attack or severe heart failure); serious lung conditions (such as severe COPD, pulmonary hypertension, or other significant breathing problems); or current severe infections or other unstable health conditions that the study doctor considers could affect the trial results or the person's safety.
- People who have taken certain medications that block dopamine in the 12 weeks before the first treatment visit, including older-style antipsychotics (such as haloperidol or chlorpromazine) or certain newer antipsychotics (such as risperidone, quetiapine, or clozapine).
- People with significant digestive system disorders that could affect how oral medication is absorbed, such as inflammatory bowel disease in the 12 weeks before the first treatment visit, or a history of relevant gastrointestinal surgery at any point in their life.
- People with a history of gout or kidney stones, or who have been treated for either condition, within the 2 years before the first treatment visit.
- People who have a known allergy or sensitivity to any ingredient in the study medication.
- People who have taken part in another clinical trial involving an investigational treatment, medical device, or surgical procedure within 4 weeks before the first screening visit (note: participation in observational studies that do not involve any intervention may still be eligible — confirm with trial site).
- Women who are breastfeeding or who have a positive pregnancy test at the first treatment visit, and who are considered to have childbearing potential (women considered not to have childbearing potential include those who have been through menopause for at least 1 year, have had surgery resulting in infertility, or have hormone test results confirming post-menopausal status).
- Women with childbearing potential, or men whose partners have childbearing potential, who are unwilling to use at least two highly effective forms of contraception (one of which must be a barrier method) from the time of signing consent until the end of the study or early withdrawal — acceptable methods include hormonal contraception, an intrauterine device or system, or barrier methods such as condoms or diaphragms.
- People who are employees of the trial site, the study sponsor, or any organisation directly involved in running the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If you need support right now
This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.
If you or someone else is in immediate danger, call 000.
- Lifeline — 24/7 crisis support: 13 11 14
- Suicide Call Back Service — 24/7 counselling: 1300 659 467
- 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
- Beyond Blue — 24/7 mental health support: 1300 22 4636
- Emergency: 000
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.
Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Principal Investigator: Tu-Hsueh YEH, M.D., Department of Neurology, Taipei Medical University Hospital
Phone: +886-2-26270835
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants experiencing adverse events (AE) and serious adverse events (SAE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.